

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Herve Bazin and Dominique Latinne

Serial No.

09/056,072

Art Unit:

1642

Filed

April 7, 1998

Examiner:

Unassigned

For

LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Activation

and Proliferation

Commissioner of Patents & Trademarks

Washington, D.C. 20231

Attn: Application Processing Division Customer Correction Branch

REQUEST TO CORRECT FILING RECEIPT

SIR:

Applicants request that the filing receipt (a copy of which is attached) be corrected. Please correct the first name of the inventor Latinne to read: "DOMINIQUE".

Please also add the priority information to read:

"WHICH IS A CIP OF 08/407,009 03/29/95 ABN WHICH IS A CIP OF 08/119,032 09/09/93 ABN WHICH IS A CIP OF 08/027,008 03/05/93 ABN"

Please issue a corrected filing receipt as requested above.

Also, enclosed is a self-addressed postage paid postcard.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents.

Washington, DC 20231, Attention: Application Processing Division, Customer Correction Branch

Raymond J. Lillie, Esq.

Date

Respectfully submitted,

Raymond J. Lillie


Reg. No. 31,778

CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN

Six Becker Farm Road Roseland, NJ 07068

W:\B\BioTransplant, Inc\#221 filing receipt correction.doc

P. 0-103X





UNITED STATES DL RTMENT OF COMMERCE Fatent and Trad main Office
ASSISTANT SECRETARY AND COMMISSIONER:
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/056,072	04/07/98	1642	\$790.00	61750221	53	14	3

49) 1 49) 1

CARELLA BYRNE BAIN GILFILLAN CECCHI, STEWART & OLSTEIN 6 BECKER FRAM ROAD ROSELAND NJ 07068

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by chack or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

) (i...)

Applicant(s)

HERVE BAZIN, BRUSSELS, BELGIUM; DOMINUQUE LATINNE, BRUSSELS, BELGIUM.

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A DIV OF 08/472,281 06/07/95 PAT 5,766,592 WHICH IS A CIP OF 05/407.009 03/39/95 ABN WHICH IS A CIP OF 05/119.032 03/09/93 ABN WHICH IS A CIP OF 08/037,008 03/05/93 ABN

TITLE

LO-CD2A ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION

PRELIMINARY CLASS: 424

T :	TE RECEIVED: 5-4-98
	TES ENTERED:
!	
: -	
00	СКЕТЕД БҮ: 1
E CAL	

100

i di.

air. Bi EC: LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

· Air.

1-di

۱.

3

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.62 which meets the provisions of 37 CFR 5.15(a). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).